Encompass 医疗
EHC
127.87
+0.10
+0.08%
Encompass 医疗
US · EHC
#1326 按市值排名
上市于 1970
127.87
+0.10
+0.08%
实时 - 追踪5344个代码 - 心跳于525秒前
· 2026-10-16 17:21
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了4家。
- 机构持股总比例下降了0.2个百分点。
机构持股
- 机构持股比例
- 99.35% -0.22pp
- 机构数量
- 702 -4
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund78.82%
Hedge Fund11.38%
Public Company3.62%
Government Pension Fund1.84%
Private Company1.65%
Sovereign Wealth Fund1.17%
Individual/Insider0.82%
Insurance Company0.46%
Government0.20%
主要股东 截至 2026-06-30
BlackRock
10.63% · 10.48M 股
T. Rowe Price Group, Inc.
5.22% · 5.15M 股
Vanguard Capital Management, LLC
5.17% · 5.10M 股
Vanguard Portfolio Management, LLC
4.99% · 4.92M 股
Wellington Management Group
3.32% · 3.28M 股
State Street Global Advisors
3.23% · 3.19M 股
Citadel Advisors LLC
2.60% · 2.56M 股
AllianceBernstein
2.51% · 2.47M 股
Fuller & Thaler Asset Management, Inc.
2.49% · 2.46M 股
Two Sigma Investments, LP
2.30% · 2.27M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 31次买入 · 19次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Mark Tarr | Chief Executive Officer | 0.27% |
| Douglas Coltharp | Chief Financial Officer | 0.24% |
| Edmund Fay | Senior Vice President | 0.09% |
| John Darby | General Counsel | 0.08% |
| Andrew Price | Chief Accounting Officer | 0.07% |
| Patrick Tuer | EVP & Chief Operating Officer | 0.03% |
| Christopher Reidy | Independent Director | 0.02% |
| Elissa Charbonneau | Chief Medical Officer | 0.02% |
| Gregory Carmichael | Independent Director | 0.00% |
| Kevin O'Connor | Independent Director | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-30 | Andrew Price | Chief Accounting Officer | Open Market Disposition | -5,211 | $120.93 |
| 2026-08-30 | John Darby | General Counsel | Derivative Exercise and Sale | -4,858 | $35.06–121.09 |
| 2026-08-09 | Douglas Coltharp | Chief Financial Officer | Open Market Disposition | -18,869 | $125.38 |
| 2026-08-09 | Mark Tarr | Chief Executive Officer | Open Market Disposition | -173,148 | $125.46–126.06 |
| 2026-08-09 | John Darby | General Counsel | Open Market Disposition | -8,906 | $125.95 |
| 2026-07-15 | Christopher Reidy | Independent Director | Other Acquisition | +340 | $112.40 |
| 2026-07-15 | Edward Christie | Director | Other Acquisition | +259 | $112.43 |
| 2026-07-14 | Joan Herman | Independent Director | Other Acquisition | +85 | -- |
| 2026-07-14 | Leslye Katz | Independent Director | Other Acquisition | +85 | -- |
| 2026-07-14 | Nancy Schlichting | Independent Director | Other Acquisition | +40 | -- |
| 2026-07-14 | Gregory Carmichael | Independent Director | Other Acquisition | +29 | -- |
| 2026-07-14 | Cain Hayes | Director | Other Acquisition | +4 | -- |
| 2026-07-14 | Kevin O'Connor | Independent Director | Other Acquisition | +19 | -- |
| 2026-07-14 | Terrance Williams | Independent Director | Other Acquisition | +29 | -- |
| 2026-05-14 | Douglas Coltharp | Chief Financial Officer | Derivative Exercise and Sale | -27,694 | $32.94–107.28 |
| 2026-05-10 | Patrick Tuer | EVP & Chief Operating Officer | Open Market Disposition | -682 | $104.56 |
| 2026-05-06 | Joan Herman | Independent Director | Other Acquisition | +1,634 | -- |
| 2026-05-06 | Leslye Katz | Independent Director | Other Acquisition | +1,634 | -- |
| 2026-05-06 | Nancy Schlichting | Independent Director | Other Acquisition | +1,634 | -- |
| 2026-05-06 | Gregory Carmichael | Independent Director | Other Acquisition | +1,634 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 17:21:26 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Encompass 医疗 讨论区 0 条评论